PARP inhibition is currently considered as a novel molecular target drug for cancer therapy [11,14]; however, side effects of available PARP inhibitors have not been fully examined in clinical trials, in vivo or in vitro studies [16]. This evidence concerns the gene PARP1 and cancer.